Weekly Digital Marketing / SEO Briefing — Cosentyx

Week ending August 30, 2026

1. Content opportunities this week

1. Administration and injection guide
   Real question: “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?”
   Why: Six long but heavily hedged answers rely on generic instructions and repeatedly defer to the device insert. Cross-response inconsistencies cover infection risk, contraindications, and allergic reactions—an opportunity for a clear, device-specific, citable guide.

2. Pregnancy, breastfeeding, and infant live-vaccine guidance
   Real question: “Can Cosentyx be used during pregnancy or breastfeeding, and what guidance does the label give about live vaccines for infants exposed in utero or via lactation?”
   Why: Answers are relatively short (230–314 words), frequently hedged, and disagree on contraindication language. A label-based page should clearly separate pregnancy, lactation, placental exposure, and infant vaccine considerations.

3. Cosentyx plaque-psoriasis dosing
   Real question: “For Cosentyx dosing in plaque psoriasis, what loading regimen and maintenance dose should I follow?”
   Why: Responses are very thin (47–111 words) and inconsistent about when maintenance begins. A structured dosing page, with regimen tables and product/indication qualifiers, could become the definitive source.

4. IL-17 mechanism explainer
   Real question: “What IL-17 role does Cosentyx target, and how is that commonly described compared with other psoriasis medicines?”
   Why: All six answers are only 85–126 words and largely generic. A concise but authoritative explainer comparing IL-17A, TNF, IL-12/23, and IL-23 pathways would address a clear information gap.

2. Where competitors may be winning visibility

Humira appears most often in Cosentyx answers this week (15 mentions), especially the question: “How does Cosentyx compare with Humira for treating plaque psoriasis—are there differences people notice in effectiveness or side effects?” Every answer names Humira.

Stelara, Enbrel, and Taltz each appear 14 times. They are concentrated in:

• Cosentyx versus Stelara practical differences
• Whether Cosentyx is “stronger” than Enbrel
• Cosentyx versus Taltz shared-decision conversations
• Broader mechanism/dosing comparisons

These comparison pages are the clearest opportunities to increase Cosentyx visibility in answers about Cosentyx itself.

3. Topics worth resolving with authoritative content

• Pregnancy/breastfeeding and infant live vaccines: Resolve the disagreement over whether guidance is a contraindication, precaution, or individualized risk–benefit decision.
• Boxed warning versus major safety warning: “What boxed warnings or major safety warnings apply to Cosentyx?” requires a definitive distinction; answer variants conflict on whether a boxed warning exists.
• Administration: Cover pen, syringe, infusion eligibility, storage, preparation, injection steps, and escalation points for allergic reaction or infection—without relying on generic biologic instructions.

4. Prioritization — recurring vs. one-off

Safety, infection, IBD, contraindication, and hedging signals recur throughout the six-week history, making them durable content investments. Dosing, pediatric use, pregnancy/lactation, and biosimilar/generic questions also recur across most weeks.

This week’s 120 responses are down from 140, while question volume is unchanged and inconsistency flags rose from 26 to 29. That favors improving existing recurring pages rather than chasing isolated queries. Remicade mentions rose to 6 from 4, while Bimzelx appeared once; these are emerging signals, not yet standalone priorities.

5. Recommended content actions

1. Publish/update the administration guide for the exact injection/storage question; prioritize due to repeated inconsistencies and high hedging.
2. Create a label-based pregnancy, breastfeeding, and infant-vaccine page; recurring topic with direct disagreement across answers.
3. Build a definitive plaque-psoriasis dosing table; short answers and inconsistent timing make this an immediate SEO/GEO gap.
4. Publish “Cosentyx vs Humira for plaque psoriasis” covering effectiveness evidence, onset, side effects, and patient-reported practical differences; Humira appears in all six answers.
5. Create a clinician-facing comparison hub covering Cosentyx vs Taltz, Stelara, and Enbrel, anchored to the exact real questions above.